FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019108567> ?p ?o ?g. }

• W2019108567 endingPage "671" @default.
• W2019108567 startingPage "663" @default.
• W2019108567 abstract "The epothilone B analogue, ixabepilone, binds to β-tubulin, is effective for taxane-refractory metastatic breast cancer (MBC), and may be given every 3 weeks or weekly. We evaluated the efficacy of weekly ixabepilone (I) plus trastuzumab (T) and carboplatin (C) as first line therapy in HER2 + MBC. Patients with HER2+ (3+ by IHC or FISH amplified) MBC received I (15 mg/m2 IV) and C (area under the curve, AUC = 2 IV) on days 1, 8, and 15 of a 28-day cycle for a maximum of 6 cycles, plus weekly T (4 mg/kg loading dose then 2 mg/kg IV) during chemotherapy then every 3 weeks (6 mg/kg IV) until disease progression. The primary objective was to determine whether the combination was associated with a response rate (RR) of at least 75%. Fifty-nine patients were treated, and 39 had HER2 overexpression confirmed in a central lab (cHER2+). For all treated patients, objective response occurred in 26 patients (44%; 95% CI 31–58%), median time to progression was 8.2 months (95% CI 6.3–9.9), and median overall survival was 34.7 months (95% CI 25.7 to [not reached]). Results were comparable for cHer2+ cancers. Grade 3–4 adverse events included neutropenia (49%), thrombocytopenia (14%), fatigue (12%), nausea (7%), diarrhea (7%), and neuropathy (7%). One patient died from treatment complications during cycle 1. Weekly ixabepilone and carboplatin plus trastuzumab have an acceptable toxicity profile, but are not likely to be associated with an RR of 75% in HER2+ MBC. Efficacy appears comparable to paclitaxel, carboplatin, and trastuzumab." @default.
• W2019108567 created "2016-06-24" @default.
• W2019108567 creator A5039809944 @default.
• W2019108567 creator A5042271475 @default.
• W2019108567 creator A5065306642 @default.
• W2019108567 creator A5066769011 @default.
• W2019108567 creator A5069872243 @default.
• W2019108567 creator A5071194144 @default.
• W2019108567 creator A5080276829 @default.
• W2019108567 creator A5085028425 @default.
• W2019108567 creator A5085875361 @default.
• W2019108567 date "2009-12-10" @default.
• W2019108567 modified "2023-09-26" @default.
• W2019108567 title "A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial" @default.
• W2019108567 cites W1946759281 @default.
• W2019108567 cites W2003278673 @default.
• W2019108567 cites W2011228443 @default.
• W2019108567 cites W2028353414 @default.
• W2019108567 cites W2039387344 @default.
• W2019108567 cites W2070116427 @default.
• W2019108567 cites W2073533584 @default.
• W2019108567 cites W2076811098 @default.
• W2019108567 cites W2100757336 @default.
• W2019108567 cites W2101100140 @default.
• W2019108567 cites W2102880631 @default.
• W2019108567 cites W2112901840 @default.
• W2019108567 cites W2119974083 @default.
• W2019108567 cites W2123528875 @default.
• W2019108567 cites W2126620646 @default.
• W2019108567 cites W2136791645 @default.
• W2019108567 cites W2139248078 @default.
• W2019108567 cites W2140837341 @default.
• W2019108567 cites W2143673928 @default.
• W2019108567 cites W2145042104 @default.
• W2019108567 cites W2147081651 @default.
• W2019108567 cites W2148860061 @default.
• W2019108567 cites W2155808778 @default.
• W2019108567 cites W2165824128 @default.
• W2019108567 cites W2256852093 @default.
• W2019108567 cites W2318605753 @default.
• W2019108567 cites W2410543190 @default.
• W2019108567 cites W4293241248 @default.
• W2019108567 doi "https://doi.org/10.1007/s10549-009-0658-9" @default.
• W2019108567 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3133687" @default.
• W2019108567 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20012354" @default.
• W2019108567 hasPublicationYear "2009" @default.
• W2019108567 type Work @default.
• W2019108567 sameAs 2019108567 @default.
• W2019108567 citedByCount "37" @default.
• W2019108567 countsByYear W20191085672012 @default.
• W2019108567 countsByYear W20191085672013 @default.
• W2019108567 countsByYear W20191085672014 @default.
• W2019108567 countsByYear W20191085672015 @default.
• W2019108567 countsByYear W20191085672016 @default.
• W2019108567 countsByYear W20191085672019 @default.
• W2019108567 countsByYear W20191085672023 @default.
• W2019108567 crossrefType "journal-article" @default.
• W2019108567 hasAuthorship W2019108567A5039809944 @default.
• W2019108567 hasAuthorship W2019108567A5042271475 @default.
• W2019108567 hasAuthorship W2019108567A5065306642 @default.
• W2019108567 hasAuthorship W2019108567A5066769011 @default.
• W2019108567 hasAuthorship W2019108567A5069872243 @default.
• W2019108567 hasAuthorship W2019108567A5071194144 @default.
• W2019108567 hasAuthorship W2019108567A5080276829 @default.
• W2019108567 hasAuthorship W2019108567A5085028425 @default.
• W2019108567 hasAuthorship W2019108567A5085875361 @default.
• W2019108567 hasBestOaLocation W20191085672 @default.
• W2019108567 hasConcept C121608353 @default.
• W2019108567 hasConcept C126322002 @default.
• W2019108567 hasConcept C143998085 @default.
• W2019108567 hasConcept C197934379 @default.
• W2019108567 hasConcept C2775930923 @default.
• W2019108567 hasConcept C2776694085 @default.
• W2019108567 hasConcept C2777063308 @default.
• W2019108567 hasConcept C2777511904 @default.
• W2019108567 hasConcept C2778239845 @default.
• W2019108567 hasConcept C2778375690 @default.
• W2019108567 hasConcept C2779194965 @default.
• W2019108567 hasConcept C2779786085 @default.
• W2019108567 hasConcept C2780580376 @default.
• W2019108567 hasConcept C2781451048 @default.
• W2019108567 hasConcept C530470458 @default.
• W2019108567 hasConcept C71924100 @default.
• W2019108567 hasConcept C90924648 @default.
• W2019108567 hasConceptScore W2019108567C121608353 @default.
• W2019108567 hasConceptScore W2019108567C126322002 @default.
• W2019108567 hasConceptScore W2019108567C143998085 @default.
• W2019108567 hasConceptScore W2019108567C197934379 @default.
• W2019108567 hasConceptScore W2019108567C2775930923 @default.
• W2019108567 hasConceptScore W2019108567C2776694085 @default.
• W2019108567 hasConceptScore W2019108567C2777063308 @default.
• W2019108567 hasConceptScore W2019108567C2777511904 @default.
• W2019108567 hasConceptScore W2019108567C2778239845 @default.
• W2019108567 hasConceptScore W2019108567C2778375690 @default.
• W2019108567 hasConceptScore W2019108567C2779194965 @default.
• W2019108567 hasConceptScore W2019108567C2779786085 @default.
• W2019108567 hasConceptScore W2019108567C2780580376 @default.
• W2019108567 hasConceptScore W2019108567C2781451048 @default.

• next